source
- AbbVie signs up to $757M deal with Beijing's Brise Pharma for two preclinical migraine candidatesAbbVie announced a discovery and commercialization agreement with Brise Pharma, a Beijing-based biotech company. The partnership covers two preclinical migraine programs and is valued at up to $75…
- FDA approves generic lenacapavir for low-income markets; EMA to review Lundbeck's Deanxit over safety concernsThe U.S. Food and Drug Administration has granted approval for a generic version of lenacapavir, a drug aimed at treating HIV, with the intention of making it available to lower-income countries.…